Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers

(University of Texas M. D. Anderson Cancer Center) Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers. Open-label Phase II study at MD Anderson reports on four cancer types.